🇺🇸 Natalizumab (Tysabri) in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 12

Most-reported reactions

1. Asthenia — 2 reports (16.67%)
2. Pyrexia — 2 reports (16.67%)
3. Abdominal Pain — 1 report (8.33%)
4. Acute Prerenal Failure — 1 report (8.33%)
5. Adrenal Insufficiency — 1 report (8.33%)
6. Adrenocortical Insufficiency Acute — 1 report (8.33%)
7. Bradycardia — 1 report (8.33%)
8. Chronic Obstructive Pulmonary Disease — 1 report (8.33%)
9. Convulsion — 1 report (8.33%)
10. Cytomegalovirus Infection — 1 report (8.33%)

Source database →

Frequently asked questions

Is Natalizumab (Tysabri) approved in United States?

Natalizumab (Tysabri) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Natalizumab (Tysabri) in United States?

Cornerstone Health Care, PA is the originator. The local marketing authorisation holder may differ — check the official source linked above.